Racial disparity in the genomics of precision oncology of prostate cancer
Abstract Background Significant racial disparities in prostate cancer incidence and mortality have been reported between African American Men (AAM), who are at increased risk for prostate cancer, and European American Men (EAM). In most of the studies carried out on prostate cancer, this population...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1867 |
| _version_ | 1828716220946317312 |
|---|---|
| author | Tu Le Pilar Soto Rojas Mary Fakunle Franklin W. Huang |
| author_facet | Tu Le Pilar Soto Rojas Mary Fakunle Franklin W. Huang |
| author_sort | Tu Le |
| collection | DOAJ |
| description | Abstract Background Significant racial disparities in prostate cancer incidence and mortality have been reported between African American Men (AAM), who are at increased risk for prostate cancer, and European American Men (EAM). In most of the studies carried out on prostate cancer, this population is underrepresented. With the advancement of genome‐wide association studies, several genetic predictor models of prostate cancer risk have been elaborated, as well as numerous studies that identify both germline and somatic mutations with clinical utility. Recent Findings Despite significant advances, the AAM population continues to be underrepresented in genomic studies, which can limit generalizability and potentially widen disparities. Here we outline racial disparities in currently available genomic applications that are used to estimate the risk of individuals developing prostate cancer and to identify personalized oncology treatment strategies. While the incidence and mortality of prostate cancer are different between AAM and EAM, samples from AAM remain to be unrepresented in different studies. Conclusion This disparity impacts the available genomic data on prostate cancer. As a result, the disparity can limit the predictive utility of the genomic applications and may lead to the widening of the existing disparities. More studies with substantially higher recruitment and engagement of African American patients are necessary to overcome this disparity. |
| first_indexed | 2024-03-12T14:09:17Z |
| format | Article |
| id | doaj.art-fcb52321eb594175b964c4b89ced3d50 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-03-12T14:09:17Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-fcb52321eb594175b964c4b89ced3d502023-08-21T10:55:52ZengWileyCancer Reports2573-83482023-09-016S1n/an/a10.1002/cnr2.1867Racial disparity in the genomics of precision oncology of prostate cancerTu Le0Pilar Soto Rojas1Mary Fakunle2Franklin W. Huang3Division of Hematology and Oncology, Department of Medicine University of California San Francisco California USADivision of Hematology and Oncology, Department of Medicine University of California San Francisco California USADepartment of Urology University of California San Francisco California USADivision of Hematology and Oncology, Department of Medicine University of California San Francisco California USAAbstract Background Significant racial disparities in prostate cancer incidence and mortality have been reported between African American Men (AAM), who are at increased risk for prostate cancer, and European American Men (EAM). In most of the studies carried out on prostate cancer, this population is underrepresented. With the advancement of genome‐wide association studies, several genetic predictor models of prostate cancer risk have been elaborated, as well as numerous studies that identify both germline and somatic mutations with clinical utility. Recent Findings Despite significant advances, the AAM population continues to be underrepresented in genomic studies, which can limit generalizability and potentially widen disparities. Here we outline racial disparities in currently available genomic applications that are used to estimate the risk of individuals developing prostate cancer and to identify personalized oncology treatment strategies. While the incidence and mortality of prostate cancer are different between AAM and EAM, samples from AAM remain to be unrepresented in different studies. Conclusion This disparity impacts the available genomic data on prostate cancer. As a result, the disparity can limit the predictive utility of the genomic applications and may lead to the widening of the existing disparities. More studies with substantially higher recruitment and engagement of African American patients are necessary to overcome this disparity.https://doi.org/10.1002/cnr2.1867clinical trial enrollmentDecipher testgermline and somatic testpolygenic risk scoresprostate cancerracial disparity |
| spellingShingle | Tu Le Pilar Soto Rojas Mary Fakunle Franklin W. Huang Racial disparity in the genomics of precision oncology of prostate cancer Cancer Reports clinical trial enrollment Decipher test germline and somatic test polygenic risk scores prostate cancer racial disparity |
| title | Racial disparity in the genomics of precision oncology of prostate cancer |
| title_full | Racial disparity in the genomics of precision oncology of prostate cancer |
| title_fullStr | Racial disparity in the genomics of precision oncology of prostate cancer |
| title_full_unstemmed | Racial disparity in the genomics of precision oncology of prostate cancer |
| title_short | Racial disparity in the genomics of precision oncology of prostate cancer |
| title_sort | racial disparity in the genomics of precision oncology of prostate cancer |
| topic | clinical trial enrollment Decipher test germline and somatic test polygenic risk scores prostate cancer racial disparity |
| url | https://doi.org/10.1002/cnr2.1867 |
| work_keys_str_mv | AT tule racialdisparityinthegenomicsofprecisiononcologyofprostatecancer AT pilarsotorojas racialdisparityinthegenomicsofprecisiononcologyofprostatecancer AT maryfakunle racialdisparityinthegenomicsofprecisiononcologyofprostatecancer AT franklinwhuang racialdisparityinthegenomicsofprecisiononcologyofprostatecancer |